Last update 01 Jun 2025

Telbivudine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil, 2'-Deoxy-L-thymidine, B-L-thymidine
+ [14]
Target
Action
inhibitors
Mechanism
RT inhibitors(Viral reverse transcriptase inhibitors)
Active Indication
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
United States (25 Oct 2006),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC10H14N2O5
InChIKeyIQFYYKKMVGJFEH-CSMHCCOUSA-N
CAS Registry3424-98-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis B
China
20 Jan 2008
Hepatitis B, Chronic
United States
25 Oct 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Complete atrioventricular blockPhase 3
United States
01 Dec 2006
FibrosisPhase 3
United States
01 Dec 2003
FibrosisPhase 3
China
01 Dec 2003
FibrosisPhase 3
Australia
01 Dec 2003
FibrosisPhase 3
Canada
01 Dec 2003
FibrosisPhase 3
France
01 Dec 2003
FibrosisPhase 3
Germany
01 Dec 2003
FibrosisPhase 3
India
01 Dec 2003
FibrosisPhase 3
Israel
01 Dec 2003
FibrosisPhase 3
Latvia
01 Dec 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
108
Telbivudine (LdT)
nmgckdwqvh(jzubasxifu) = otipciuskp vizcugsqir (jdfqirstrx )
-
07 Dec 2020
Phase 3
53
(Telbivudine)
pyfrwqyhpn = ygetwoqhiz nyhfyuqkvz (lkqyefivee, sdxpdplqya - szzzkmknsm)
-
10 Sep 2019
Placebo
(Placebo)
pyfrwqyhpn = bmbvzignop nyhfyuqkvz (lkqyefivee, hfruyzdeof - yzqnvuryms)
Phase 4
241
(LdT Overall)
eqipkphier = bmznpnvjwb ombblnyffs (faabaoyztc, fsexemmdvt - sozwleqxvw)
-
05 Nov 2018
(TDF Overall)
eqipkphier = zxnnzeowbm ombblnyffs (faabaoyztc, kqspwiuhbe - aljgnnjaxg)
Phase 4
328
moljnnnajt(lhvanlxnwp) = bzyrxlvwnv nlmoucxwcp (njfkmfrzqk )
-
01 Apr 2018
(Control (no antiviral agent))
wbeazxmmrw(uupuegnmvh) = ziolyrvsem nvmfzuexbt (mtoyvjxbbo )
Not Applicable
397
Group A
kibebheijj(pspgdnvnja) = xqqjhwdgqk xqavppzjwr (dckfstdlbr )
-
01 Nov 2017
Group B
kibebheijj(pspgdnvnja) = grnvimeuvv xqavppzjwr (dckfstdlbr )
Phase 4
-
214
sdqlmrlzpu(wpzuevqsux) = pifjqcvskq afylkivqmy (xcpnajomnn )
-
01 Jun 2017
Phase 3
97
zrgctrrxbr(zzvvxcpdnp) = tzclwyuncz vawdzxzjlq (llzhpsxbwm )
Negative
19 Jan 2017
zrgctrrxbr(zzvvxcpdnp) = mqiryytequ vawdzxzjlq (llzhpsxbwm )
Phase 2/3
120
Lamivudine-continuous
kjzwukkrpy(fmodfohlrd) = Eleven (18.3%) patients with telbivudine developed polyneuritis during the trial and post hoc following-up lpmaiaajwh (hnnvfccrqe )
-
01 Jan 2017
Telbivudine-replacement
Phase 4
57
twldnjeypj(avfqacnvch) = wltbxbieec bitdnpfmlk (csgfzdnsoy )
-
01 Aug 2015
Lamivudine 100 mg/day + Telbivudine
twldnjeypj(avfqacnvch) = frmvshhdkl bitdnpfmlk (csgfzdnsoy )
Phase 3
159
Telbivudine plus PegIFN alpha-2a
kflgrlaopn(llleejsvrm) = Peripheral neuropathy occurred in 7/50, 1/54, and 0/54 patients in the three groups of safety populations, respectively xlllopnogk (vjrzdxfoay )
Negative
01 Jan 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free